Generic Name and Formulations:
Anidulafungin 50mg/vial, 100mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free; contains fructose and mannitol.
Indications for ERAXIS:
Candidemia. Esophageal candidiasis. Other Candida infections (intra-abdominal abscess, peritonitis).
Give by IV infusion; max rate 1.1mg/minute. Candidiasis, intra-abdominal abscess, peritonitis: 200mg on day 1, then 100mg/day for at least 14 days after last positive culture. Esophageal candidiasis: 100mg on day 1, then 50mg/day for at least 14 days and at least 7 days after symptom resolution.
≤16yrs: not established.
Follow-up if hepatic dysfunction develops. Discontinue and treat appropriately if anaphylactic reactions occur. Pregnancy: avoid. Nursing mothers.
Glucan synthesis inhibitor (echinocandin).
Hypokalemia, GI upset, pyrexia, insomnia, anemia, headache, dyspepsia; hepatic effects, infusion reactions, anaphylactic reactions.
Fecal, renal (minor).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|